HTB homepage • Conference reports • Articles by subject • Subscribe June 2016 Contents Editorial May/June 2016: Volume 17 Number 5/6 In memory In Memory: Paul Blanchard, cofounder HIV i-Base Treatment alerts NHS England confuses arse and elbow: block to PrEP ignores UK HIV crisis and will send PEP services into chaos Conference reports 22nd Annual BHIVA Conference, 19-22 April 2016, Manchester New HBV drugs and non-viral liver disease in HIV positive people Non-AIDS mortality in England and Wales in HIV positive vs general population High prevalence of multiple high-risk HPV infections in young HIV positive gay men Anal cancer and HPV screening in HIV positive people Increasing demand for community treatment information services Non alcohol fatty acid liver disease: an emerging problem HIV positive people on ART have impaired alveolar immunity International Liver Congress (EASL) 2016, 13-18 April 2016, Barcelona High cure rates using generic hepatitis C drugs bought online: EASL supports lower cost access for Western countries Studies of new generic $300 HepC combination of ravidasvir and sofosbuvir for low-income countries 23rd Conference on Retroviruses and Opportunistic Infections (CROI 2016), 22-25 February 2016, Boston No effect of tenofovir on infant bone mineral content in African study Use of modelling to predicting paediatric dosing of long acting antiretrovirals Nevirapine dosing for treatment of neonates START substudies: increased quality of life from earlier treatment but no impact on vascular function or cardiovascular markers Six-week ledipasvir/sofosbuvir in HIV positive patients with acute HCV 6th International Workshop on HIV & Women, 20-21 February 2016, Boston Doravirine can be co-administered with oral contraceptives No increased risk of birth defects with darunavir: findings from the Antiretroviral Pregnancy Registry Antiretrovirals FTC/TAF dual-nuke approved in the US and Europe Paediatric labeling expanded, and additional tablet strengths for FTC/TDF Treatment access Timeline for access to generic dolutegravir: what still needs to be done Botswana “Treat All” programme will move to universal treatment with dolutegravir as first-line ART South Africa takes bold step to provide HIV treatment for all Side effects Persistent HPV infection may be related to tissue type in HIV positive people On the web Community reports PDFs May/June 2016: Volume 17 Number 5/6 HTB homepage • Conference reports • Articles by subject • Subscribe
